BIIB033

{{Short description|Monoclonal antibody}}

{{Infobox drug

| type = mab

| image =

| alt =

| mab_type =

| source =

| target =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status = Investigational

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action=

| excretion =

| CAS_number = 1884474-47-8

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = Anti-LINGO-1

}}

BIIB033 (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.{{Cite web|title = Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test|url = https://www.forbes.com/sites/matthewherper/2015/04/14/biogen-ms-drug-results-are-mildly-encouraging-in-eye-disease-test/|website = Forbes|access-date = 2015-10-13}}{{ClinicalTrialsGov|NCT01864148|Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex}}{{cite journal | vauthors = Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D | display-authors = 6 | title = Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033 | journal = Neurology | volume = 1 | issue = 2 | pages = e18 | date = August 2014 | pmid = 25340070 | pmc = 4202679 | doi = 10.1212/NXI.0000000000000018 }}